Literature DB >> 1493371

Role of magnetic resonance imaging in thyroid-associated ophthalmopathy: its predictive value for therapeutic outcome of immunosuppressive therapy.

Y Hiromatsu1, K Kojima, N Ishisaka, K Tanaka, M Sato, K Nonaka, H Nishimura, H Nishida.   

Abstract

To investigate the efficacy of magnetic resonance imaging (MRI) in the assessment of thyroid-associated ophthalmopathy (TAO), 51 patients with TAO were evaluated by ophthalmologic examinations and MRI at 0.5 T. Thickness of extraocular muscles (EM) was measured by T1-weighted image. Signal intensities of EM and orbital connective tissue (OCT) were measured by short inversion time inversion recovery (STIR) image and expressed as a ratio by comparison to the signal intensity of cerebral substantia alba (SI, signal intensity ratio). Significant enlargement of one or more EM was observed in 86% of patients with TAO, and SI of EM (2.15 +/- 0.63, mean +/- SD) was significantly increased compared with control values (n = 16; 1.35 +/- 0.33; t test, p < 0.01). SI of OCT tended to be greater than that in the control group, although the difference was not significant. There was a significant positive correlation between thickness of EM and severity of ophthalmopathy, assessed as an ophthalmopathy index (p < 0.05). SI of neither EM nor OCT correlated with the severity of the eye disease. To investigate whether MRI findings could predict the outcome of methylprednisolone pulse therapy, we studied 23 patients with TAO who received this treatment. SI of EM and OCT in the 12 patients giving favorable responses were significantly greater than those in the 11 patients without good response (t test, p < 0.01). On the other hand, the thickness of eye muscles did not correlate with the outcome of treatment except for that of medial rectus muscle. There was a significant correlation between SI of EM and that of OCT (r = 0.78, p < 0.01), suggesting possible similar pathologic processes in these tissues in TAO.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1493371     DOI: 10.1089/thy.1992.2.299

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  15 in total

1.  Slow-release lanreotide in Graves' ophthalmopathy: A double-blind randomized, placebo-controlled clinical trial.

Authors:  T-C Chang; S-L Liao
Journal:  J Endocrinol Invest       Date:  2006-05       Impact factor: 4.256

2.  Update on advanced imaging options for thyroid-associated orbitopathy.

Authors:  Michael P Rabinowitz; Jacqueline R Carrasco
Journal:  Saudi J Ophthalmol       Date:  2012-10

3.  Predicting the response to glucocorticoid therapy in thyroid-associated ophthalmopathy: mobilizing structural MRI-based quantitative measurements of orbital tissues.

Authors:  Hao Hu; Xiao-Quan Xu; Lu Chen; Wen Chen; Qian Wu; Huan-Huan Chen; Hui Zhu; Hai-Bin Shi; Fei-Yun Wu
Journal:  Endocrine       Date:  2020-06-05       Impact factor: 3.633

4.  Use of MRI signal intensity of extraocular muscles to evaluate methylprednisolone pulse therapy in thyroid-associated ophthalmopathy.

Authors:  Tomoaki Higashiyama; Yasuhiro Nishida; Katsutaro Morino; Satoshi Ugi; Yoshihiko Nishio; Hiroshi Maegawa; Masahito Ohji
Journal:  Jpn J Ophthalmol       Date:  2014-12-03       Impact factor: 2.447

5.  Orbital Fat Volumetry and Water Fraction Measurements Using T2-Weighted FSE-IDEAL Imaging in Patients with Thyroid-Associated Orbitopathy.

Authors:  Y Kaichi; K Tanitame; H Itakura; H Ohno; M Yoneda; Y Takahashi; Y Akiyama; K Awai
Journal:  AJNR Am J Neuroradiol       Date:  2016-06-30       Impact factor: 3.825

Review 6.  Recent developments in Graves' ophthalmopathy imaging.

Authors:  G J Kahaly
Journal:  J Endocrinol Invest       Date:  2004-03       Impact factor: 4.256

7.  Clinical and imaging evaluation of the response to intravenous steroids in patients with Graves' orbitopathy and analysis on who requires additional therapy.

Authors:  Theodora Tsirouki; Alexandra Bargiota; Stelios Tigas; Agathi Vasileiou; Eftichia Kapsalaki; Zoe Giotaki; Ioannis Asproudis; Agathokles Tsatsoulis; Georgios Koukoulis; Evangelia E Tsironi
Journal:  Clin Ophthalmol       Date:  2016-11-17

8.  Liver Dysfunction Associated with Intravenous Methylprednisolone Pulse Therapy in Patients with Graves' Orbitopathy.

Authors:  Hiroyuki Eguchi; Junichi Tani; Saori Hirao; Munehisa Tsuruta; Ichiro Tokubuchi; Kentaro Yamada; Masataka Kasaoka; Yasuo Teshima; Tatsuyuki Kakuma; Yuji Hiromatsu
Journal:  Int J Endocrinol       Date:  2015-06-28       Impact factor: 3.257

9.  Relationship between magnetic resonance imaging signal intensity and volume of extraocular muscles in thyroid-associated ophthalmopathy with methylprednisolone pulse therapy.

Authors:  Tomoaki Higashiyama; Yasuhiro Nishida; Masahito Ohji
Journal:  Clin Ophthalmol       Date:  2016-04-20

Review 10.  Genetic Associations of Interleukin-related Genes with Graves' Ophthalmopathy: a Systematic Review and Meta-analysis.

Authors:  Kah Hie Wong; Shi Song Rong; Kelvin K L Chong; Alvin L Young; Chi Pui Pang; Li Jia Chen
Journal:  Sci Rep       Date:  2015-11-18       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.